Eyckerman, Sven
Titeca, Kevin
Van Quickelberghe, Emmy
Cloots, Eva
Verhee, Annick
Samyn, Noortje
De Ceuninck, Leentje
Timmerman, Evy
De Sutter, Delphine
Lievens, Sam
Van Calenbergh, Serge
Gevaert, Kris
Tavernier, Jan
Article History
Received: 10 April 2015
Accepted: 22 March 2016
First Online: 28 April 2016
Competing interests
: J.T. is scientific founder, CTO and holds equity in Orionis Biosciences, a recently founded company that will develop the three-hybrid aspects of Virotrap. All other authors declare no competing financial interests.